Active substanceHopantenic acidHopantenic acid
Similar drugsTo uncover
  • Hopantam®
    pills inwards 
    ALTAYVITAMINS, CJSC     Russia
  • Hopantenic acid
    pills inwards 
    ATOLL, LLC     Russia
  • Calcium Gopantenate®
    pills inwards 
  • Pantogam®
    pills inwards 
    PIK-PHARMA, LLC     Russia
  • Pantogam®
    syrup inwards 
    PIK-PHARMA, LLC     Russia
  • Pantogam®
    pills inwards 
    PIK-PHARMA, LLC     Russia
  • Pantogam®
    pills inwards 
    PIK-PHARMA, LLC     Russia
  • Pantocalcin®
    pills inwards 
    VALENTA PHARM, PAO     Russia
  • Panthotropil
    pills inwards 
    KVADRAT-S, LLC     Russia
  • Dosage form: & nbsppills
    Composition:

    1 tablet contains:

    active substance: calcium gopantenate (Pantogam®) 500 mg;

    Excipients: methylcellulose 1.6 mg, calcium stearate 6.2 mg, magnesium hydroxycarbonate 93.6 mg, talc 18.6 mg.

    Description:Tablets of white color, flat-cylindrical, with a facet and a risk.
    Pharmacotherapeutic group:nootropic remedy
    ATX: & nbsp

    N.06.B.X   Other psychostimulants and nootropic drugs

    Pharmacodynamics:

    The spectrum of action of Pantogam® is related to the presence of gamma-aminobutyric acid in its structure. The mechanism of action is due to the direct influence of Pantogam® on GABAB- receptor-channel complex. The drug has nootropic and anticonvulsant action.Pantogam® improves brain resistance to hypoxia and the effects of toxic substances, stimulates anabolic processes in neurons, combines moderate sedation with mild stimulating effect, reduces motor excitability, activates mental and physical performance. It improves the metabolism of GABA in chronic alcohol intoxication and after the abolition of ethanol. It is able to inhibit the acetylation reactions involved in the mechanisms of inactivation of procaine (novocaine) and sulfonamides, thereby prolonging the action of the latter. It causes inhibition of the pathologically increased vesicle reflex and detrusor tone.

    Pharmacokinetics:

    Pantogam® is rapidly absorbed from the gastrointestinal tract, penetrates the blood-brain barrier, the highest concentrations are created in the liver, kidneys, in the wall of the stomach and skin. The drug is not metabolized and is excreted unchanged for 48 hours: 67.5% from the accepted dose - with urine, 28,5% - with feces.

    Indications:

    - Cognitive impairment of organic brain lesions, including those with consequences of neuroinfections, craniocerebral trauma and neurotic disorders;

    - at extrapyramidal hyperkinesias in patients with hereditary diseases of the nervous system in combination with the therapy;

    - as a corrector for side effects of neuroleptic drugs, with neuroleptic extrapyramidal syndrome (hyperkinetic and akinetic), as part of complex therapy for cerebral insufficiency in patients with schizophrenia;

    - epilepsy with retardation of mental processes in complex therapy with anticonvulsants;

    - psycho-emotional overload, decreased mental and physical performance, to improve concentration and memorization;

    - neurogenic disorders of urination (pollakiuria, imperative urges, mandatory urinary incontinence, enuresis);

    - children with developmental delay (mental, speech, motor, or their combination), including against the background of perinatal encephalopathy and in children with various forms of infantile cerebral palsy;

    - children with hyperkinetic disorders (attention deficit hyperactivity syndrome);

    - children with neurosis-like conditions (tics, with stuttering, mainly with clonic form).

    Contraindications:

    - Dhypersensitivity;

    - acute severe kidney disease;

    - pregnancy;

    - lactation;

    - children under 3 years.

    Pregnancy and lactation:

    The drug is not recommended for use in pregnant and lactating women due to lack of efficacy and safety data.

    Dosing and Administration:

    Inside 15-30 minutes after eating. A single dose for adults is usually 0.25-1 g (1/2-2 tablets), for children - 0.25-0.5 g (1/2 -1 tablet); The daily dose for adults is 1.5-3 g (3-6 tablets), for children 0.75-3 g (1.5-6 tablets). The course of treatment is from 1 to 4 months, in some cases up to 6 months. After 3-6 months, a repeat course of treatment is possible.

    In cases of cognitive impairment with organic brain lesions, including those with consequences of neuroinfections and craniocerebral trauma, and neurotic disorders: to 0.25 g (1/2 tablets) 3-4 times a day.

    When extrapyramidal hyperkinesis in patients with hereditary diseases of the nervous system in combination with ongoing therapy: in a dose of 0.5 to 3 g (1-6 tablets) per day. The course of treatment - up to 4 or more months.

    As a corrector for side effects of neuroleptics, with neuroleptic extrapyramidal syndrome (hyperkinetic and akinetic), as part of a complex therapy for cerebral insufficiency in patients with schizophrenia: adults - in a dose of 0.5 to 1 g (1-2 tablets) 3 times a day; children - in a dose of 0.25 to 0.5 g (1/2-1 tablet) 3-4 times a day. The course of treatment is 1-3 months.

    With epilepsy with the slowing down of mental processes in complex therapy with anticonvulsants: adults - in a dose of 0.5 to 1 g (1-2 tablets) 3 times a day; children - in a dose of 0.25 to 0.5 g (1/2 -1 tablet) 3-4 times a day. The course of treatment is up to 6 months.

    With psycho-emotional overload, a decrease in mental and physical performance, to improve concentration and memorization: to 0.25 g (1/2 tablets) 3 times a day.

    With neurogenic disorders of urination: adults - in a dose of 0.5 to 1 g (1-2 tablets) 2-3 times a day; children - in a dose of 0.25 to 0.5 g (1/2-1 tablet) 3 times a day (the daily dose is 25-50 mg / kg). The course of treatment is 1 -3 months.

    Children with various pathologies of the nervous system depending on the age of the drug is recommended to take up to 3 grams per day (6 tablets). Tactics of prescribing the drug: increasing the dose for 7-12 days, taking in the maximum dose for 15-40 days and gradually reducing the dose until Pantogam® is canceled within 7-8 days. The break between the exchange rates of Pantogam®, as well as for any other nootropic remedy, is from 1 to 3 months.

    Children with developmental delay: on 0,5 g (1 tablet) 3-4 times a day. The course of treatment is 2-3 months.

    Children with attention deficit hyperactivity disorder depending on the body weight, the drug is prescribed at an average therapeutic dose of 30 mg / kg per day, in the morning and in the afternoon, with titration of the dose for the first 5-7 days. The course of treatment is 3-4 months.

    Children with neurosis-like conditions (tics, with stuttering, mainly with a clonic form): in a dose of 0.25 to 0.5 g (1/2 -1 tablet) 3-6 times a day. The course of treatment is 1-4 months.

    Given the nootropic effect of the drug, it is preferably taken in the morning and afternoon (up to 17 hours).

    Side effects:

    Allergic reactions are possible (rhinitis, conjunctivitis, skin allergic reactions). In this case, cancel the drug.

    Very rarely noted adverse reactions from the central nervous system (hyperexcitation, sleep disturbance or drowsiness, lethargy, inhibition, headache, dizziness, noise in the head). In this case, reduce the dose of the drug.

    Overdose:

    Sleep disturbances or drowsiness, noise in the head.

    Treatment: Activated carbon, gastric lavage, symptomatic therapy.

    Interaction:

    Prolongs the effect of barbiturates, enhances the action anticonvulsants, prevents side effects of phenobarbital, carbamazepine, neuroleptics.

    The effect of Pantogam® is enhanced in combination with glycine, etidronic acid.

    Potentsiruet action of local anesthetics (procaine).

    Special instructions:

    In the conditions of long-term treatment, simultaneous administration of the drug with other nootropic and stimulating agents is not recommended.

    The drug is used in children older than 3 years. At an earlier age, it is recommended to take the drug in the form of a syrup.

    Effect on the ability to drive transp. cf. and fur:

    In the first days of taking the drug should be careful when driving vehicles and mechanisms, given the possible occurrence of drowsiness (see section "Possible side effects with the use of the drug").

    Form release / dosage:

    Tablets, 500 mg.

    Packaging:

    For 10 tablets in a contour mesh box made of polyvinyl chloride film and aluminum foil.

    5 contour mesh packages together with the instruction for use are placed in a pack of cardboard.

    Storage conditions:

    In a dry, protected from light place, at a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    3 years.

    Do not use after expiry date.

    Terms of leave from pharmacies:On prescription
    Registration number:LP-000860
    Date of registration:14.10.2011
    Date of cancellation:2016-10-14
    The owner of the registration certificate:PIK-PHARMA, LLC PIK-PHARMA, LLC Russia
    Manufacturer: & nbsp
    Representation: & nbspPIK-PHARMA LLC PIK-PHARMA LLC Russia
    Information update date: & nbsp23.12.2015
    Illustrated instructions
      Instructions
      Up